Jennifer Quinn
Internal Medicine · Oneida, NYNPI 1952670069
Payments from drug & device makers
Across 583 payments — averaging $16.26 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$1K
- GSK$891
- AstraZeneca$709
- Boehringer Ingelheim$620
- Amgen$614
- Novo Nordisk$605
- plus $5K from 36 others
What the payments were for
- Food & beverage$9,446100%
- Education$320%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
How this compares
$9,478 in reported general payments places this provider in the 90th percentile of 9,771 internal medicine providers in New York.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 98 | $134,955 |
| OzempicSemaglutide | 66 | $64,546 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 61 | $60,285 |
| TrulicityDulaglutide | 52 | $55,501 |
| MyrbetriqMirabegron | 34 | $34,010 |
| JardianceEmpagliflozin | 21 | $28,493 |
| MounjaroTirzepatide | 23 | $23,304 |
| FarxigaDapagliflozin Propanediol | 21 | $21,003 |
| LinzessLinaclotide | 13 | $13,607 |
| Breo ElliptaFluticasone/Vilanterol | 16 | $12,806 |
| Spiriva RespimatTiotropium Bromide | 17 | $11,962 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 17 | $11,225 |
| Tresiba Flextouch U-100Insulin Degludec | 11 | $6,819 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 162 | $6,200 |
| Incruse ElliptaUmeclidinium Bromide | 14 | $4,354 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis | $494 | $134,95598 claims |
| GSKTrelegy Ellipta, Breo Ellipta, Incruse Ellipta, Arnuity Ellipta | $891 | $80,856103 claims |
| Lilly USA, LLCTrulicity, Mounjaro | $372 | $78,80575 claims |
| Novo NordiskOzempic | $605 | $64,54666 claims |
| Boehringer IngelheimJardiance, Spiriva Respimat | $620 | $40,45538 claims |
| Astellas Pharma US IncMyrbetriq | $290 | $34,01034 claims |
| AstraZenecaFarxiga, Breztri Aerosphere | $709 | $32,22738 claims |
| AbbVieLinzess, Synthroid | $1,456 | $14,62432 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 9,771 internal medicine providers in New York.
Other internal medicine in Oneida
- Helena YuNew York$50.9M
- Neha KordeNew York$21.2M
- Karen AutioNew York$18.5M
- Ingo MellinghoffNew York$16.1M
- Gopakumar IyerNew York$12.4M
- David DoveEast Hampton$12.3M
- Robert CupeloEast Syracuse$10.6M
- Patrick ReaganRochester$9.4M
- Sally LauNew York$8.4M
- Angela BrancheRochester$7.9M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.